Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPPIK: Sparsentan in Pediatric Proteinuric Glomerular Diseases
2021-000621-27Phase 2Completed
- Sponsor
- Travere Therapeutics
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sparsentan in glomerulopathy and focal segmental glomerulosclerosis (FSGS), sponsored by Travere Therapeutics. Primary endpoint: Treatment-emergent adverse events. Started Jul 2021; status: completed.
02
Drugs
sparsentan
03
Conditions
glomerulopathyfocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2021-000621-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000621-27.